Trillium Therapeutics Inc. announced the appointment of pharmaceutical industry leader Paolo Pucci to its Board of Directors, effective immediately. Most recently, Mr. Pucci served as Chief Executive Officer of the targeted therapeutics oncology company, ArQule, until it was acquired by Merck for $2.7 billion in January 2020.